Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 12:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 1,836 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo- C Clear all
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis

NCT06119529
View directory record Official record
Conditions
Healthy, Atopic Dermatitis
Interventions
LY3872386, Prednisone, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Anaheim, California • Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 30, 2026, 12:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate Ad35-GRIN/ENV HIV Vaccine in Healthy Adult Volunteers

NCT00851383
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
Ad35-GRIN/ENV, Ad35-GRIN
Biological
Lead sponsor
International AIDS Vaccine Initiative
Network
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 25, 2012 · Synced Oct 30, 2026, 12:29 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors

NCT02009631
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Colon Cancer, Lung Cancer, Gastric Cancer, Solid Tumors
Interventions
Veliparib (ABT-888), Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Scottsdale, Arizona • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 30, 2026, 12:29 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Development of Agents to Diminish the Risk of Hypoglycemia-induced Brain Injury in Type 1 Diabetes

NCT03356457
View directory record Official record
Conditions
Hyperglycaemia (Diabetic)
Interventions
Dichloroacetate, Placebo oral capsule
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 30, 2026, 12:29 PM EDT
Completed Not applicable Interventional

Impact of Maternal Pomegranate Juice on Brain Injury in Infants With Intrauterine Growth Restriction (IUGR)

NCT00788866
View directory record Official record
Conditions
Intrauterine Growth Restriction
Interventions
Pomegranate Juice, Placebo
Dietary Supplement
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 17, 2014 · Synced Oct 30, 2026, 12:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of BITS7201A in Healthy Volunteers and Participants With Mild Atopic Asthma

NCT02748642
View directory record Official record
Conditions
Mild Atopic Asthma
Interventions
BITS7201A, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 30, 2026, 12:29 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

NCT00703118
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Telaprevir, Peg-IFN-alfa-2a, Ribavirin, Placebo
Drug
Lead sponsor
Tibotec BVBA
Industry
Eligibility
18 Years to 70 Years
Enrollment
663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
31
States / cities
Birmingham, Alabama • Coronado, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2014 · Synced Oct 30, 2026, 12:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults

NCT01479296
View directory record Official record
Conditions
HIV Infections
Interventions
VRC rAd5 vaccine (rAd5 gag-pol/env A/B/C), rAd5 env A, rAd5 env B, rAd5 env C, rAd5 gag-pol, Placebo Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
8
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 30, 2026, 12:29 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)

NCT00697203
View directory record Official record
Conditions
Dyslipidemia
Interventions
Placebo, Pravastatin, Dalcetrapib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
33
States / cities
Mobile, Alabama • Scottsdale, Arizona • Newark, Delaware + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Oct 30, 2026, 12:29 PM EDT
Completed Phase 2 Interventional Results available

A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery

NCT03891524
View directory record Official record
Conditions
Arthroplasty, Replacement, Knee
Interventions
JNJ-70033093 25 mg, JNJ-70033093 50 mg, JNJ-70033093 100 mg, JNJ-70033093 200 mg, Placebo, Enoxaparin 40 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
50 Years and older
Enrollment
1,242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 30, 2026, 12:29 PM EDT
Completed Phase 2 Interventional

A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease

NCT00403286
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Fluticasone Propionate/Formoterol Fumarate, Fluticasone Propionate, Formoterol Fumarate, Fluticasone Propionate/Salmeterol Xinafoate, Placebo
Drug
Lead sponsor
Dey
Industry
Eligibility
40 Years and older
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
49
States / cities
Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2009 · Synced Oct 30, 2026, 12:29 PM EDT
Completed Not applicable Interventional

Reflexology: An Intervention for Advanced Breast Cancer

NCT01577420
View directory record Official record
Conditions
Breast Cancer
Interventions
Reflexology Sessions, Placebo Sessions
Other
Lead sponsor
Michigan State University
Other
Eligibility
21 Years and older · Female only
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
12
States / cities
Evanston, Illinois • Flint, Michigan • Grand Rapids, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2012 · Synced Oct 30, 2026, 12:29 PM EDT
Completed Phase 2 Interventional

Vitamin D3 Supplementation for Heart Failure Patients

NCT01636570
View directory record Official record
Conditions
Heart Failure, Vitamin D Deficiency, Cardiomyopathy, Congestive Heart Failure
Interventions
Placebo Comparator: Sugar Pill, Vitamin D3 (cholecalciferol)
Drug
Lead sponsor
Heidi Moretti, MS, RD
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Missoula, Montana
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 30, 2026, 12:29 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma

NCT04099251
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab, Placebo
Biological · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Enrollment
790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
32
States / cities
Birmingham, Alabama • Tucson, Arizona • Springdale, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 30, 2026, 12:29 PM EDT
Recruiting Phase 1Phase 2 Interventional

Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)

NCT04715022
View directory record Official record
Conditions
Hypertension, Cardiovascular Diseases
Interventions
Ascorbic acid solution (American Regent Laboratories Inc.), Saline
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
35 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 30, 2026, 12:29 PM EDT
Recruiting Phase 2 Interventional

SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

NCT07187531
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
High Dose SAB-142, Low Dose SAB-142, Placebo
Drug · Other
Lead sponsor
SAb Biotherapeutics, Inc.
Industry
Eligibility
5 Years to 40 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
22
States / cities
San Francisco, California • San Jose, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 30, 2026, 12:29 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)

NCT07159841
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Interventions
Atumelnant, Placebo
Drug
Lead sponsor
Crinetics Pharmaceuticals Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
10
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 30, 2026, 12:29 PM EDT
Terminated Phase 2 Interventional Results available

Relieving Acute Pain (RAP) Study: A Pilot Study

NCT03426137
View directory record Official record
Conditions
Trauma, Opioid Use, Spine Fusion
Interventions
Oxycodone, Ketorolac, Placebo
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 30, 2026, 12:29 PM EDT
Completed Phase 2 Interventional Results available

A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

NCT02413372
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis
Interventions
BMS-986036, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years to 75 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
17
States / cities
Rialto, California • San Diego, California • Indianapolis, Indiana + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Oct 30, 2026, 12:29 PM EDT
Active, not recruiting Phase 2 Interventional

Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)

NCT05743244
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Abrocitinib 200 MG Oral Tablet, Ritlecitinib, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
12 Years to 35 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
23
States / cities
Orange, California • Palo Alto, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 30, 2026, 12:29 PM EDT
Completed Phase 2 Interventional

Single-dose Crossover Study to Evaluate the Early Bronchodilating Effect of FlutiForm HFA pMDI in Adult Subjects With Mild to Moderate Asthma

NCT00734292
View directory record Official record
Conditions
Mild to Moderate Asthma
Interventions
fluticasone propionate, formoterol fumarate, fluticasone propionate, formoterol fumarate
Drug · Other
Lead sponsor
SkyePharma AG
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
8
States / cities
Anaheim, California • Mission Viejo, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 30, 2026, 12:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Chitin-Glucan on Oxidized Low-Density Lipoprotein (LDL)

NCT01232309
View directory record Official record
Conditions
Cardiovascular
Interventions
Chitin-Glucan, Low Dose Chitin-Glucan, Low Dose Chitin-Glucan + Olive Extract, Placebo
Dietary Supplement
Lead sponsor
Stratum Nutrition
Industry
Eligibility
21 Years to 70 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Addison, Illinois • Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 23, 2012 · Synced Oct 30, 2026, 12:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3015014 in Healthy Participants With Elevated Low Density Lipoprotein Cholesterol

NCT01426412
View directory record Official record
Conditions
Hyperlipidemia
Interventions
LY3015014 IV, Placebo IV, LY3015014 SC, Placebo SC
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
3
States / cities
Glendale, California • Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Oct 30, 2026, 12:29 PM EDT
Withdrawn Phase 4 Interventional

Prospective Trial of Oral Vancomycin Therapy vs. Placebo for Prevention of CDI

NCT04241744
View directory record Official record
Conditions
CDI
Interventions
Vancomycin 125 MG po BID
Drug
Lead sponsor
Creighton University
Other
Eligibility
65 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 30, 2026, 12:29 PM EDT